Summary MaSTherCell SA (MaSTherCell), a subsidiary of Orgenesis Inc is a contract development and manufacturing organization that offers cell therapy products.The organization offers services such as technology transfer, process and assay development; manufacturing, quality management and logistic services.
It offers GMP infrastructures are designed to be adapted to our customers’ specific needs, from technology transfer to the delivery of cell therapy products.The organization offers quality management services for identity, purity, stability, safety and potency of cells.
It offers its quality manufacturing services to the cell therapy communities in Europe. MaSTherCell is headquartered in Gosselies, Belgium.
MaSTherCell SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
Regenerative medicine market to register a CAGR of 23.8% from 2019 to 2024 The regenerative medicine market is projected to reach USD 38.7 billion by 2024 from USD 13.3 billion in 2019, at a CAGR of 23.8% during the forecast period. The rising global incidence of cancer, increasing global aging population, and technological...
The Global Gene Therapy Partnering Agreements 2014-2019 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in gene therapy partnering deals Disclosed headlines, upfronts, milestones and royalties by stage...
The Global Cancer Monoclonal Antibody Partnering 2014-2019: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in cancer monoclonal antibody partnering...
501 pages •
By Roots Analysis Private Ltd.
• Mar 2019
INTRODUCTION Chronic disorders, such as diabetes, cancer, heart disease, obesity, and certain types of mental health problems, are considered among the leading causes of death and disability across the globe. According to a report published by the Center for Managing Chronic Disease at the University of Michigan in 2018,...
The North America genome editing market is expected to reach US$ 4,148.1 Mn in 2025 from US$ 1,234.5 Mn in 2017. The market is estimated to grow with a CAGR of 17.2% from 2018-2025. The growth of the genome editing market is primarily attributed to the rise in the production of genetically modified crops and rising prevalence of the genetic...